ANIP (ANI Pharmaceuticals) Current Accrued Expense: $113.8 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ANIP ANI Pharmaceuticals Inc ANIP
89 GF Score
Price $76.56
GF Value $96.61
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is ANI Pharmaceuticals Current Accrued Expense?

ANI Pharmaceuticals ANIP +2.40% 89 Current Accrued Expense is $113.8 Mil as of Jun. 2026. GuruFocus rates ANIP with a GF Score™ of 89/100 and a GF Value™ of $96.61 (Modestly Undervalued). The stock has 2 warning signs investors should review.

ANI Pharmaceuticals's Current Accrued Expense for the quarter that ended in Jun. 2026 was $113.8 Mil.

ANI Pharmaceuticals's quarterly Current Accrued Expense declined from Dec. 2025 ($108.5 Mil) to Mar. 2026 ($86.1 Mil) but then increased from Mar. 2026 ($86.1 Mil) to Jun. 2026 ($113.8 Mil).

ANI Pharmaceuticals's annual Current Accrued Expense increased from Dec. 2023 ($34.1 Mil) to Dec. 2024 ($55.1 Mil) and increased from Dec. 2024 ($55.1 Mil) to Dec. 2025 ($108.5 Mil).

ANI Pharmaceuticals Current Accrued Expense Related Terms

ANI Pharmaceuticals Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for ANI Pharmaceuticals's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ANI Pharmaceuticals Current Accrued Expense Chart

ANI Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 19.37 25.57 34.05 55.08 108.45

ANI Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 83.66 102.23 108.45 86.08 113.80
ANIP
89GF Score
ANI Pharmaceuticals Inc ANIP
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ANI Pharmaceuticals Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $113.8 Mil mean?
ANI Pharmaceuticals (ANIP) has a Current Accrued Expense of $113.8 Mil as of Jun. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on ANI Pharmaceuticals and its competitors.
Is ANI Pharmaceuticals' Current Accrued Expense too high?
ANI Pharmaceuticals' current Current Accrued Expense is $113.8 Mil. Overall, ANI Pharmaceuticals has a GF Score™ of 89/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ANI Pharmaceuticals' Current Accrued Expense compare to TRLV and AMLX?
ANI Pharmaceuticals' Current Accrued Expense of $113.8 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Drug Manufacturers company?
A good Current Accrued Expense depends on the Drug Manufacturers industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on ANI Pharmaceuticals and its competitors. ANI Pharmaceuticals's current Current Accrued Expense is $113.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ANI Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, ANI Pharmaceuticals (ANIP) is currently considered Modestly Undervalued. The stock's GF Value™ is $96.61, compared to a current price of $76.56 — trading 20.8% below its estimated fair value. The current Current Accrued Expense is $113.8 Mil. ANI Pharmaceuticals' overall GF Score™ is 89/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For ANI Pharmaceuticals (ANIP), the current Current Accrued Expense is $113.8 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ANI Pharmaceuticals (ANIP) Overvalued in 2026?

Based on GuruFocus' analysis, ANI Pharmaceuticals stock appears to be undervalued. The current stock price of $76.56 is trading 20.8% below its estimated GF Value™ of $96.61. GuruFocus considers ANI Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for ANIP:

  • Current Accrued Expense: $113.8 Mil
  • GF Value™: $96.61 vs. price of $76.56 (20.8% below fair value)
  • GF Score™: 89/100 with 2 warning signs

No single metric tells the full story. See the ANIP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ANI Pharmaceuticals Business Description

Other Exchanges BSFA:Germany
Address 210 Main Street West, Baudette, MN, USA, 56623
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.
89GF Score

Get the complete analysis for ANIP

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$76.56
Price
$96.61
GF Value